#Genentech employee shuttle: here’s what we do, here’s our podcast
#Apple / #Google shuttles: run silent run deep, please don’t egg us
I keep reading about the great job report, but I am tired of it. My son has been trying forever to get a job. He has a Master's in Biology, and that apparently isn't good enough. I am so frustrated for him. He interviews constantly, but just ... reasons. Ideally, he would love to work with Fish and Wildlife. Or Genentech. But I think at this point he just wants a job.
🔍 Explore Advanced Data Visualization Techniques!
👨💻 Presented by Daniel Sjoberg, Software Engineer at Genentech, our latest webinar on "Visualizing Survival Data with the ggsurvfit R Package" is now available. Perfect for those who love digging deep into data with R!
🎥 Stream it here: https://www.r-consortium.org/r-medicine-webinar-visualizing-survival-data-with-the-ggsurvfit-r-package
R/Medicine Webinar: Visualizing Survival Data with the {ggsurvfit} R Package This webinar focused on the {ggsurvfit} R package, a tool designed to simplify the creation of time-to-event or survival analysis...
A 2009 study, cited as a “key scientific discovery” by Genentech as it sought a higher valuation, has now been retracted by former University head Marc Tessier-Lavigne. It is his fourth retraction in as many months.
"In 2009, Marc Tessier-Lavigne, then a top executive at the biotechnology company #Genentech, was the primary author of a #scientific paper published in the prestigious journal Nature that claimed to have found the potential cause for brain degeneration in #Alzheimer’s patients.
[…] Neither a correction nor a retraction was issued, and the paper stands to this day."
Impressive investigation by #TheoBaker: https://stanforddaily.com/2023/02/17/internal-review-found-falsified-data-in-stanford-presidents-alzheimers-research-colleagues-allege/ #medicines #authorship #science #historyOfScience #ethics 🧶
His paper was called “the miracle result.” But it never turned into an Alzheimer’s treatment. Now, four former Genentech senior scientists and executives allege that an internal review in 2011 discovered the paper had been based on fabricated research — and that Marc Tessier-Lavigne kept the results of the review from becoming public. He denies the allegations.
My latest clinical pipeline column for @NatureMedicine is out today.
It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody
for relapsed or refractory follicular #lymphoma.
#FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment
#COVID NEWS (USA)
#FDA approved a new indication for the #monoclonal #antibody tocilizumab (Actemra, #Genentech) for treatment of hospitalized adults with #COVID19 receiving systemic corticosteroids and requiring supplement oxygen, mechanical ventilation (invasive or non-invasive), or #ECMO.
Robert Swanson was born on this day in 1947. Swanson was one of the founders of Genentech, the first company dedicated to genetic engineering.
#ThisDayInBiotech #Biotechnology #Biotech #RobertSwanson #Genentech #GENE
SMARCA2 has been identified as a synthetic lethal target in SMARCA4 mutated tumors, however, homology between the two has hindered the development of selective SMARCA2 inhibitors. Here, the authors synthesize a proteolysis targeting chimera (PROTAC) capable of SMARCA2 specific degradation and demonstrate its utility in the treatment of SMARCA4 mutated tumors.
cancergrace
Manish Vij
Angie
R Consortium
El Club De Los Físicos Muertos
Eric Maugendre on collectives
Thiago Carvalho
Monica Di, PhD 
WhatisBiotechnology
Keith Hornberger